Home>Topics>Stocks>Momenta Pharmaceuticals

Momenta Pharmaceuticals MNTA

  1. All
  2. Commentary
  3. Headlines
    1. Anika Therapeutics: A Recent Greenblatt Small Cap Biotech Pick

      Headlines

      Tue, 16 Sep 2014

      screen for drug companies with market cap> $500M on 10/17/2012 identified Exelixis (NASDAQ: EXEL ), Momenta (NASDAQ: MNTA ), Pozen (NASDAQ: POZN ), and Questcor (NASDAQ: QCOR ). An equally weighted portfolio containing these two losers

    2. Teva Proves You Cannot Escape The Patent Cliff

      Headlines

      Thu, 4 Sep 2014

      s revenue could vanish. The Copaxone patent expired on May 24, 2014, which caused Mylan Inc. (NASDAQ: MYL ) Novartis AG (NYSE: NVS ) , and Momenta Pharmaceuticals (NASDAQ: MNTA ) to apply to the US Food and Drug Complete Story »

    3. U.S. Supreme Court Decision is Minor Plus for Teva

      Commentary

      Mon, 31 Mar 2014

      Likewise, the news is a slight negative for two of the major contenders attempting a generic Copaxone: Momenta Pharmaceuticals and Mylan. Negative shifts in our fair value estimates for both of these companies from potential generic

    4. Momenta Awaits Potential Generic Copaxone Decision

      Commentary

      Wed, 6 Nov 2013

      We’re leaving our fair value estimate for Momenta Pharmaceuticals unchanged after the company reported third-quarter results within our expectations. Momenta reported a net loss of $25.4 million

    5. Patent Litigation Creates Earlier-Than-Expected Generic Copaxone Launch Opportunity

      Commentary

      Fri, 2 Aug 2013

      We're raising our fair value estimate for Momenta Pharmaceuticals to $16 per share after updating our forecast for a potential generic Copaxone launch to 2014 from 2015 following the recent U

    6. Teva Faces Patent Setback on Copaxone Following Momenta and Mylan Appeal

      Commentary

      Fri, 26 Jul 2013

      decision is a positive for the two major contenders attempting to manufacture generic versions of Copaxone, Mylan MYL and Momenta MNTA . We may slightly increase our fair value estimates for both of these firms as we reevaluate our assumptions. We plan to adjust

    7. Competition in Generic Lovenox Market Remains Headwind for Momenta in 2013

      Commentary

      Tue, 30 Apr 2013

      Momenta Pharmaceutical's MNTA first-quarter results mostly met our expectations, but volatility from market share shifts and pricing pressure in the generic

    8. Rebound in Generic Lovenox Helps Momenta's Fourth-Quarter Results

      Commentary

      Fri, 15 Feb 2013

      We'll likely raise our fair value estimate for Momenta Pharmaceuticals MNTA after the company reported fourth-quarter results and issued a 2013 outlook slightly ahead of our projections. We plan to increase

    9. Momenta's Revenue Swoons on Generic Lovenox Competition

      Commentary

      Thu, 8 Nov 2012

      Competition in the generic Lovenox market caused a precipitous decline in Momenta Pharmaceuticals ' MNTA third-quarter revenue. Our forecast included price erosion, but the lackluster results were weaker than our expectations

    10. Momenta Advances Product Development Despite Setback from Copaxone Ruling

      Commentary

      Thu, 2 Aug 2012

      We don't plan to change our fair value estimate for Momenta MNTA after the company's second-quarter results mostly met our expectations. Momenta reported a 75% year-over-year decline

    « Prev1234Next »
    Content Partners